Published in Dig Dis Sci on March 13, 2013
Clinical Activity and Quality of Life Indices Are Valid Across Ulcerative Colitis But Not Crohn's Disease Phenotypes. Dig Dis Sci (2016) 0.76
On the question of ethnicity and its impact on IBD-related outcomes. Dig Dis Sci (2013) 0.75
Hospital volume and surgical mortality in the United States. N Engl J Med (2002) 25.79
Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. Am J Respir Crit Care Med (2005) 23.85
American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med (1992) 20.79
Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol (2005) 10.16
Racial and ethnic differences in access to medical care. Med Care Res Rev (2000) 6.45
Disparities in health care by race, ethnicity, and language among the insured: findings from a national sample. Med Care (2002) 5.81
Limited English proficiency and Latinos' use of physician services. Med Care Res Rev (2000) 2.80
The natural history of adult Crohn's disease in population-based cohorts. Am J Gastroenterol (2009) 2.70
Reducing racial bias among health care providers: lessons from social-cognitive psychology. J Gen Intern Med (2007) 2.49
Explaining racial and ethnic disparities in health care. Med Care (2006) 2.40
Anastomotic leaks after intestinal anastomosis: it's later than you think. Ann Surg (2007) 2.32
Use of infliximab within 3 months of ileocolonic resection is associated with adverse postoperative outcomes in Crohn's patients. J Gastrointest Surg (2008) 2.29
Variation in access to health care for different racial/ethnic groups by the racial/ethnic composition of an individual's county of residence. Med Care (2004) 2.25
Glossary of terms relating to ethnicity and race: for reflection and debate. J Epidemiol Community Health (2004) 2.19
Effect of infliximab on short-term complications in patients undergoing operation for chronic ulcerative colitis. J Am Coll Surg (2007) 1.97
Corticosteroids and immunomodulators: postoperative infectious complication risk in inflammatory bowel disease patients. Gastroenterology (2003) 1.94
Has there been a change in the natural history of Crohn's disease? Surgical rates and medical management in a population-based inception cohort from Western Hungary between 1977-2009. Am J Gastroenterol (2012) 1.89
Time trends in therapies and outcomes for adult inflammatory bowel disease, Northern California, 1998-2005. Gastroenterology (2009) 1.74
Racial/ethnic differences in surgical outcomes in veterans following knee or hip arthroplasty. Arthritis Rheum (2005) 1.72
Impact of hospital volume on postoperative morbidity and mortality following a colectomy for ulcerative colitis. Gastroenterology (2008) 1.56
Risk factors for intra-abdominal sepsis after surgery in Crohn's disease. Dis Colon Rectum (2000) 1.52
An interaction of race and ethnicity with socioeconomic status in rectal cancer outcomes. Ann Surg (2011) 1.49
The natural history of pediatric ulcerative colitis: a population-based cohort study. Am J Gastroenterol (2009) 1.29
Early postoperative complications are not increased in patients with Crohn's disease treated perioperatively with infliximab or immunosuppressive therapy. Am J Gastroenterol (2004) 1.27
Factors affecting colectomy rate in ulcerative colitis: an epidemiologic study. Gut (1990) 1.26
Outcomes of patients with Crohn's disease improved from 1988 to 2008 and were associated with increased specialist care. Gastroenterology (2011) 1.24
Corticosteroids but not infliximab increase short-term postoperative infectious complications in patients with ulcerative colitis. Inflamm Bowel Dis (2009) 1.22
Diverging racial and ethnic disparities in access to physician care: comparing 2000 and 2007. Med Care (2012) 1.10
Perioperative treatment with infliximab in patients with Crohn's disease and ulcerative colitis is not associated with an increased rate of postoperative complications. J Gastrointest Surg (2008) 1.09
Racial, ethnic, and socioeconomic disparities in patient outcomes after craniotomy for tumor in adult patients in the United States, 1988-2004. Neurosurgery (2010) 1.07
The effect of race on coronary bypass operative mortality. J Am Coll Cardiol (2000) 1.07
Crohn's disease: does race matter? The Mid-Atlantic Crohn's Disease Study Group. Am J Gastroenterol (2000) 1.06
Diagnostic and therapeutic management of nosocomial pneumonia in surgical patients: results of the Eole study. Crit Care Med (2002) 1.03
Incidence and subsequent impact of pelvic abscess after ileal pouch-anal anastomosis for chronic ulcerative colitis. Dis Colon Rectum (1998) 1.01
Does infliximab influence surgical morbidity of ileal pouch-anal anastomosis in patients with ulcerative colitis? Dis Colon Rectum (2007) 0.99
Risk of comorbidities on postoperative outcomes in patients with inflammatory bowel disease. Arch Surg (2011) 0.99
The impact of race and insurance type on the outcome of endovascular abdominal aortic aneurysm (AAA) repair. J Vasc Surg (2008) 0.94
Factors affecting surgical risk in elderly patients with inflammatory bowel disease. J Gastrointest Surg (2002) 0.93
Preoperative steroid administration: effect on morbidity among patients undergoing intestinal bowel resection for Crohńs disease. World J Surg (2003) 0.92
Azathioprine or 6-mercaptopurine before colectomy for ulcerative colitis is not associated with increased postoperative complications. Inflamm Bowel Dis (2002) 0.92
What happens to racial and ethnic minorities after cancer surgery at American College of Surgeons National Surgical Quality Improvement Program hospitals? J Am Coll Surg (2012) 0.91
Colectomy and the incidence of postsurgical complications among ulcerative colitis patients with private health insurance in the United States. Am J Gastroenterol (2008) 0.90
Systematic review: The role of race and socioeconomic factors on IBD healthcare delivery and effectiveness. Inflamm Bowel Dis (2013) 0.89
Gender, race, and socioeconomic status affects outcomes after lung cancer resections in the United States. Ann Thorac Surg (2011) 0.87
The impact of ethnicity on outcomes following coronary artery bypass graft surgery in the Veterans Health Administration. J Am Coll Cardiol (2002) 0.83
The role of unconscious bias in surgical safety and outcomes. Surg Clin North Am (2011) 0.83
Inflammatory bowel disease: perioperative pharmacological considerations. Mayo Clin Proc (2011) 0.82
Racial disparity in amputation-free survival after infrainguinal bypass procedure: contribution of socioeconomic status. Am J Phys Med Rehabil (2009) 0.80
Demographically associated variations in outcomes after bariatric surgery. Am J Surg (2011) 0.79
Preoperative risk evaluation of postoperative morbidity in IBD patients--impact of the POSSUM score. Int J Colorectal Dis (2011) 0.75
Colon salvage therapy for acute severe colitis: cyclosporine or infliximab? Curr Opin Gastroenterol (2011) 0.75
Toll-like receptor-4 is required for intestinal response to epithelial injury and limiting bacterial translocation in a murine model of acute colitis. Am J Physiol Gastrointest Liver Physiol (2005) 4.28
Toll-like receptor-4 promotes the development of colitis-associated colorectal tumors. Gastroenterology (2007) 3.99
Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. J Exp Med (2014) 2.98
Human intestinal epithelial cells are broadly unresponsive to Toll-like receptor 2-dependent bacterial ligands: implications for host-microbial interactions in the gut. J Immunol (2003) 2.96
Cox-2 is regulated by Toll-like receptor-4 (TLR4) signaling: Role in proliferation and apoptosis in the intestine. Gastroenterology (2006) 2.78
6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterology (2002) 2.35
Thioguanine: a potential alternate thiopurine for IBD patients allergic to 6-mercaptopurine or azathioprine. Am J Gastroenterol (2003) 2.20
Chromoendoscopy-targeted biopsies are superior to standard colonoscopic surveillance for detecting dysplasia in inflammatory bowel disease patients: a prospective endoscopic trial. Am J Gastroenterol (2008) 2.16
Beta-defensin-2 expression is regulated by TLR signaling in intestinal epithelial cells. J Immunol (2004) 2.05
Antibiotic therapy in inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol (2011) 2.04
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
Safety and efficacy of adalimumab (D2E7) in Crohn's disease patients with an attenuated response to infliximab. Am J Gastroenterol (2005) 1.93
Toll-like receptor signaling in small intestinal epithelium promotes B-cell recruitment and IgA production in lamina propria. Gastroenterology (2008) 1.89
Inflammatory bowel disease is associated with an increased incidence of cardiovascular events. Am J Gastroenterol (2011) 1.88
Developing an instrument to assess the endoscopic severity of ulcerative colitis: the Ulcerative Colitis Endoscopic Index of Severity (UCEIS). Gut (2011) 1.80
American Gastroenterological Association Institute technical review on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.78
The myeloid differentiation factor 88 (MyD88) is required for CD4+ T cell effector function in a murine model of inflammatory bowel disease. J Immunol (2008) 1.75
Toll-like receptors (TLRs) and Nod-like receptors (NLRs) in inflammatory disorders. Semin Immunol (2009) 1.66
Outcome measurement in clinical trials for Ulcerative Colitis: towards standardisation. Trials (2007) 1.62
Challenges and possible solutions to colorectal cancer screening for the underserved. J Natl Cancer Inst (2014) 1.61
Placental transfer of anti-tumor necrosis factor agents in pregnant patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2012) 1.57
Innate immune signaling by Toll-like receptor-4 (TLR4) shapes the inflammatory microenvironment in colitis-associated tumors. Inflamm Bowel Dis (2009) 1.53
A genome-wide scan of Ashkenazi Jewish Crohn's disease suggests novel susceptibility loci. PLoS Genet (2012) 1.52
Defects in mucosal immunity leading to Crohn's disease. Immunol Rev (2005) 1.48
American Gastroenterological Association Institute medical position statement on corticosteroids, immunomodulators, and infliximab in inflammatory bowel disease. Gastroenterology (2006) 1.43
An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol (2011) 1.42
A novel Toll-like receptor 4 antagonist antibody ameliorates inflammation but impairs mucosal healing in murine colitis. Am J Physiol Gastrointest Liver Physiol (2009) 1.39
Exercise attenuates PCB-induced changes in the mouse gut microbiome. Environ Health Perspect (2013) 1.33
Anti-flagellin (CBir1) phenotypic and genetic Crohn's disease associations. Inflamm Bowel Dis (2007) 1.33
Constitutive activation of epithelial TLR4 augments inflammatory responses to mucosal injury and drives colitis-associated tumorigenesis. Inflamm Bowel Dis (2010) 1.28
Toll-like receptor 4 differentially regulates epidermal growth factor-related growth factors in response to intestinal mucosal injury. Lab Invest (2010) 1.23
NOD2 variants and antibody response to microbial antigens in Crohn's disease patients and their unaffected relatives. Gastroenterology (2006) 1.20
Certolizumab pegol in patients with moderate to severe Crohn's disease and secondary failure to infliximab. Clin Gastroenterol Hepatol (2010) 1.19
Glucocorticosteroid therapy in inflammatory bowel disease: systematic review and meta-analysis. Am J Gastroenterol (2011) 1.14
Clinical outcomes of patients with ulcerative colitis and co-existing Clostridium difficile infection. Dig Dis Sci (2009) 1.14
Pathogen recognition receptors, cancer and inflammation in the gut. Curr Opin Pharmacol (2009) 1.14
Reliability and initial validation of the ulcerative colitis endoscopic index of severity. Gastroenterology (2013) 1.14
Advances in the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep (2006) 1.12
Evaluation of 22 genetic variants with Crohn's disease risk in the Ashkenazi Jewish population: a case-control study. BMC Med Genet (2011) 1.10
TLR4 activates the β-catenin pathway to cause intestinal neoplasia. PLoS One (2013) 1.10
A pilot study of adalimumab in infliximab-allergic patients. Inflamm Bowel Dis (2004) 1.07
The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease. Inflamm Bowel Dis (2004) 1.05
Predictors of aggressive inflammatory bowel disease. Gastroenterol Hepatol (N Y) (2011) 1.02
Biomarkers in inflammatory bowel disease. Curr Opin Gastroenterol (2004) 1.01
Innate immunity in the small intestine. Curr Opin Gastroenterol (2012) 1.01
Innate immunity in the small intestine. Curr Opin Gastroenterol (2011) 1.01
Phenotypic manifestations of inflammatory bowel disease differ between Hispanics and non-Hispanic whites: results of a large cohort study. Am J Gastroenterol (2012) 1.00
Ulcerative colitis therapy: importance of delivery mechanisms. Rev Gastroenterol Disord (2005) 0.98
Regulation of Toll-like receptor 4-associated MD-2 in intestinal epithelial cells: a comprehensive analysis. Innate Immun (2009) 0.97
Successful use of thalidomide for refractory esophageal Crohn's disease. Am J Gastroenterol (2013) 0.95
Antibodies to I2 predict clinical response to fecal diversion in Crohn's disease. Inflamm Bowel Dis (2006) 0.94
Cancer in inflammatory bowel disease: lessons from animal models. Curr Opin Gastroenterol (2012) 0.93
The role of prostaglandin E2 (PGE 2) in toll-like receptor 4 (TLR4)-mediated colitis-associated neoplasia. BMC Gastroenterol (2010) 0.93
Hepatotoxicity of 6-mercaptopurine (6-MP) and Azathioprine (AZA) in adult IBD patients. Am J Gastroenterol (2007) 0.88
Early hepatic nodular hyperplasia and submicroscopic fibrosis associated with 6-thioguanine therapy in inflammatory bowel disease. Am J Surg Pathol (2004) 0.87
Aberrant expression of the polarity complex atypical PKC and non-muscle myosin IIA in active and inactive inflammatory bowel disease. Virchows Arch (2011) 0.87
How are Azathioprine and 6-mercaptopurine dosed by gastroenterologists? Results of a survey of clinical practice. Inflamm Bowel Dis (2008) 0.86
Improving access to colorectal cancer screening through medical philanthropy: feasibility of a flexible sigmoidoscopy health fair for uninsured patients. Am J Gastroenterol (2011) 0.86
Role of vascular endothelial growth factor and angiopoietin systems in serum of Crohn's disease patients. Inflamm Bowel Dis (2008) 0.85
Increased toll-like receptor 4 in cerebral endothelial cells contributes to the astrocyte swelling and brain edema in acute hepatic encephalopathy. J Neurochem (2013) 0.85
Microflora in colorectal cancer: a friend to fear. Nat Med (2010) 0.84
The innate immune system and inflammatory bowel disease. Scand J Gastroenterol (2015) 0.82
Combination of innate and adaptive immune alterations increased the likelihood of fibrostenosis in Crohn's disease. Inflamm Bowel Dis (2010) 0.82
Practical techniques for detection of Toll-like receptor-4 in the human intestine. Methods Mol Biol (2009) 0.82
In silico and Ex vivo approaches identify a role for toll-like receptor 4 in colorectal cancer. J Exp Clin Cancer Res (2014) 0.82
Lipopolysaccharide potentiates polychlorinated biphenyl-induced disruption of the blood-brain barrier via TLR4/IRF-3 signaling. Toxicology (2012) 0.81
Antibodies to tumor necrosis factor-alpha in the treatment of Crohn's disease. Curr Opin Drug Discov Devel (2005) 0.81
Higher Adalimumab Levels Are Associated with Histologic and Endoscopic Remission in Patients with Crohn's Disease and Ulcerative Colitis. Inflamm Bowel Dis (2016) 0.80
Benign small bowel thickening and lymphadenopathy: a manifestation of celiac disease. Dig Dis Sci (2008) 0.79
Re: underrepresentation of underrepresented minorities in academic medicine. Gastroenterology (2010) 0.79
Design issues and outcomes in IBD clinical trials. Inflamm Bowel Dis (2005) 0.79
What are toll-like receptors and what role may they have in IBD? Inflamm Bowel Dis (2008) 0.79
Use of capsule endoscopy for established Crohn's disease. Gastrointest Endosc Clin N Am (2006) 0.79
Host-microbe interactions in the small bowel. Curr Opin Gastroenterol (2015) 0.79
Gut microbiota and inflammatory bowel disease: the role of antibiotics in disease management. Postgrad Med (2014) 0.78
Superiority of the DNA amplification assay for the diagnosis of C. difficile infection: a clinical comparison of fecal tests. Dig Dis Sci (2012) 0.78
FcRL3 gene promoter variant is associated with peripheral arthritis in Crohn's disease. Inflamm Bowel Dis (2009) 0.78
What is the role and significance of serum and stool biomarkers in the diagnosis of IBD? Inflamm Bowel Dis (2008) 0.78
Genetics in diagnosing and managing inflammatory bowel disease. Gastroenterol Clin North Am (2012) 0.77
Update on idiopathic colitides. Curr Opin Gastroenterol (2013) 0.77
Harnessing the power of bacteria to protect the gut. N Engl J Med (2008) 0.77
New insights into the pathogenesis of inflammatory bowel disease. Curr Gastroenterol Rep (2004) 0.76
Gut microbes in Crohn's disease: getting to know you better? Am J Gastroenterol (2008) 0.76
Analysis of soluble angiogenic factors in Crohn's disease: a preliminary study. Gastroenterol Hepatol (2007) 0.76
Use of Cancer Stem Cells to Investigate the Pathogenesis of Colitis-associated Cancer. Inflamm Bowel Dis (2016) 0.75
Taking a closer look at the rectal examination: beyond the basics. Am J Gastroenterol (2009) 0.75
Combination therapy with infliximab and immunomodulators: is the glass half empty? Gastroenterology (2008) 0.75
Fluid volume in acute pancreatitis: how much is too much? Am J Gastroenterol (2012) 0.75
Defining subtypes of Crohn's disease patients: the ground work for translational research in inflammatory bowel disease. J Clin Gastroenterol (2003) 0.75
Is genetic testing in IBD ready for prime time? Am J Gastroenterol (2004) 0.75